Miłosz Plichta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Miłosz Plichta has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Aleksander Urbaś
1 shared publication- Aleksander Urbaś
Murcki Hospital in Katowice, Poland
1 shared publication Emil Plichta
1 shared publication- Emil Plichta
Medical University of Silesia, Katowice, Poland
1 shared publication Jan Wandzel
Wroclaw Medical University
1 shared publication- Jan Wandzel
Medical University of Silesia, Katowice, Poland
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 74005
Supportive organ management in acute right ventricular failure secondary to pulmonary embolism: a narrative review
Background. Pulmonary embolism (PE) is among the most common cardiovascular syndromes and a leading cause of acute right ventricular failure (ARVF), which drives haemodynamic and respiratory deterioration and high mortality. While causal treatment removes the thrombus, supportive organ management keeps patients alive until it takes effect, yet clear algorithms are lacking. Aim. To review the pathophysiology of ARVF in PE and available supportive (haemodynamic, oxygenation, ventilation) strategies, appraising their efficacy, safety and evidence quality. Material and methods. Narrative review of PubMed and Google Scholar (2016–2026, with justified exceptions), using Boolean combinations of terms on right ventricular failure, PE and organ support. 36 studies were narratively synthesised, each assessed for design, sample size and methodology. Results. ARVF in PE stems from RV pressure overload uncoupling contractility from afterload, causing RV dilatation, septal shift, LV underfilling and ischaemia. Supportive care targets preload, afterload and contractility. High-flow oxygen therapy appears superior to low-flow and possibly comparable to non-invasive ventilation; positive-pressure ventilation risks haemodynamic harm. Fluids require cautious titration guided by CVP and VExUS. Noradrenaline and dobutamine are preferred; levosimendan and milrinone reduce pulmonary vascular resistance but risk hypotension. Inhaled vasodilators (notably nitric oxide) and oxygen show promise but unproven benefit. Mechanical circulatory support (mainly VA-ECMO) is a bridging option, best combined with embolectomy. Conclusions. Management of ARVF in PE demands combined causal and supportive treatment, but much supportive care rests on extrapolated or low-quality evidence; PE-specific studies are needed.
- 25 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 74005
Open AccessSupportive organ management in acute right ventricular failure secondary to pulmonary embolism: a narrative review
Background. Pulmonary embolism (PE) is among the most common cardiovascular syndromes and a leading cause of acute right ventricular failure (ARVF), which drives haemodynamic and respiratory deterioration and high mortality. While causal treatment removes the thrombus, supportive organ management keeps patients alive until it takes effect, yet clear algorithms are lacking. Aim. To review the pathophysiology of ARVF in PE and available supportive (haemodynamic, oxygenation, ventilation) strategies, appraising their efficacy, safety and evidence quality. Material and methods. Narrative review of PubMed and Google Scholar (2016–2026, with justified exceptions), using Boolean combinations of terms on right ventricular failure, PE and organ support. 36 studies were narratively synthesised, each assessed for design, sample size and methodology. Results. ARVF in PE stems from RV pressure overload uncoupling contractility from afterload, causing RV dilatation, septal shift, LV underfilling and ischaemia. Supportive care targets preload, afterload and contractility. High-flow oxygen therapy appears superior to low-flow and possibly comparable to non-invasive ventilation; positive-pressure ventilation risks haemodynamic harm. Fluids require cautious titration guided by CVP and VExUS. Noradrenaline and dobutamine are preferred; levosimendan and milrinone reduce pulmonary vascular resistance but risk hypotension. Inhaled vasodilators (notably nitric oxide) and oxygen show promise but unproven benefit. Mechanical circulatory support (mainly VA-ECMO) is a bridging option, best combined with embolectomy. Conclusions. Management of ARVF in PE demands combined causal and supportive treatment, but much supportive care rests on extrapolated or low-quality evidence; PE-specific studies are needed.
- Open Access
- 13 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 68, 74319
Fecal Zonulin as a Potential Biomarker of Intestinal Barrier Dysfunction in Obesity: Molecular Mechanisms, Clinical Validation, and Methodological Challenges - Review of Literature
Introduction: Intestinal permeability is a tightly regulated physiological process that enables the transport of nutrients and ions while preventing the passage of harmful luminal antigens. The term "leaky gut" is often misused in pseudoscientific contexts, despite the existence of well-established physiological mechanisms regulating epithelial barrier function. In obesity, chronic low-grade inflammation and gut dysbiosis stimulate the secretion of zonulin, a physiological modulator of tight junctions (TJs). Increased zonulin levels promote pathological disruption of the leak pathway, contributing to systemic low-grade inflammation. Assessment of intestinal barrier integrity may have clinical value in evaluating metabolic risk and monitoring subclinical inflammation. Methods: A literature search was conducted using the PubMed/MEDLINE and Google Scholar databases. Publications addressing zonulin, intestinal permeability, obesity, fecal biomarkers, epithelial transport mechanisms, ELISA assay specificity, and clinical correlations were reviewed. Results: Higher fecal zonulin concentrations were consistently associated with increased body mass index (BMI). Clinical studies demonstrated a direct relationship between impaired intestinal barrier integrity and systemic low-grade inflammation. Weight loss improved intestinal epithelial integrity and was accompanied by favorable changes in gut microbiota composition. Conclusions: Increased intestinal permeability in obesity is a pathological consequence of tight junction dysfunction. Fecal zonulin is a validated, non-invasive biomarker of intestinal barrier impairment and may be useful for monitoring the effectiveness of metabolic interventions. However, its routine clinical application remains limited due to the need for further standardization and validation.
- 13 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 68, 74319
Open AccessFecal Zonulin as a Potential Biomarker of Intestinal Barrier Dysfunction in Obesity: Molecular Mechanisms, Clinical Validation, and Methodological Challenges - Review of Literature
Introduction: Intestinal permeability is a tightly regulated physiological process that enables the transport of nutrients and ions while preventing the passage of harmful luminal antigens. The term "leaky gut" is often misused in pseudoscientific contexts, despite the existence of well-established physiological mechanisms regulating epithelial barrier function. In obesity, chronic low-grade inflammation and gut dysbiosis stimulate the secretion of zonulin, a physiological modulator of tight junctions (TJs). Increased zonulin levels promote pathological disruption of the leak pathway, contributing to systemic low-grade inflammation. Assessment of intestinal barrier integrity may have clinical value in evaluating metabolic risk and monitoring subclinical inflammation. Methods: A literature search was conducted using the PubMed/MEDLINE and Google Scholar databases. Publications addressing zonulin, intestinal permeability, obesity, fecal biomarkers, epithelial transport mechanisms, ELISA assay specificity, and clinical correlations were reviewed. Results: Higher fecal zonulin concentrations were consistently associated with increased body mass index (BMI). Clinical studies demonstrated a direct relationship between impaired intestinal barrier integrity and systemic low-grade inflammation. Weight loss improved intestinal epithelial integrity and was accompanied by favorable changes in gut microbiota composition. Conclusions: Increased intestinal permeability in obesity is a pathological consequence of tight junction dysfunction. Fecal zonulin is a validated, non-invasive biomarker of intestinal barrier impairment and may be useful for monitoring the effectiveness of metabolic interventions. However, its routine clinical application remains limited due to the need for further standardization and validation.